23 Jul, 2026
According to Straits Research, the global clinical oncology next generation sequencing market, valued at $628.45 million in 2025, is projected to grow from $695.94 million in 2026 to $1,574.02 million by 2034 at a CAGR of 10.74% during the forecast period 2026–2034.
Clinical Oncology NGS (Next-Generation Sequencing) is a cutting-edge technology that plays a pivotal role in analyzing genetic mutations and cellular alterations within cancer cells. This process aids in making informed, personalized treatment decisions tailored to each patient's unique genetic profile.
By sequencing DNA obtained from blood samples, often through liquid biopsies or directly from tumor samples, NGS identifies actionable mutations that may drive cancer progression. Moreover, NGS allows for the monitoring of treatment responses over time, helping clinicians assess the effectiveness of therapies and adjust as needed.
Recent advancements in Next-Generation Sequencing (NGS) technologies have significantly enhanced the ability to sequence cancer-related genes in clinical settings. As NGS continues to evolve, its role in personalized and targeted cancer therapies becomes increasingly vital, driving wider adoption across various cancer subtypes.
For instance, in December 2022, Med Genome Inc. launched the TruSight Oncology 500 (TSO-500), a comprehensive NGS assay for tumor profiling. This assay is capable of detecting key genomic variants and immunotherapy biomarkers, including Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI), positioning it as a powerful tool for advancing cancer research and precision medicine.
These advancements are crucial in improving the effectiveness of cancer treatments, addressing the growing demand for tailored therapies across a range of cancer types.
An emerging opportunity within the clinical oncology NGS market is the increasing adoption of pan-cancer genomic profiling tests. These tests enable the comprehensive analysis of multiple cancer types through a single diagnostic procedure, improving both the efficiency and accuracy of cancer detection.
For example, Foundation Medicine's FoundationOne Liquid CDx leverages blood samples and NGS to detect genetic mutations in circulating cell-free DNA across more than 300 cancer-related genes. This method provides a less invasive and more streamlined approach to analyzing a wide range of cancers.
As the demand for pan-cancer genomic profiling grows, the uptake of NGS technologies is expected to accelerate, presenting significant opportunities for companies that provide advanced diagnostic solutions.
North America holds the largest share of the global clinical oncology NGS market. This growth is largely driven by the region's cutting-edge healthcare infrastructure, significant investments in genomic research, and advancements in molecular diagnostics. With a strong emphasis on personalized medicine and early cancer detection, North America remains a key player in the adoption and application of NGS technologies. Moreover, the region's dominance is reinforced by the continuous innovation and introduction of novel products by industry leaders like Thermo Fisher Scientific and Illumina.
Asia-Pacific is experiencing rapid growth in clinical oncology (NGS), driven by increasing investments in healthcare infrastructure, expanding biotechnology sectors, and a rising demand for genomic research and diagnostics. Countries like China, India, and Japan are witnessing a surge in research activities, particularly in oncology, leading to a higher demand for clinical oncology NGS technology.
sales@straitsresearch.com